Dentsply Sirona: Tariff Refunds Drive a Disciplined Quarter, But the Turnaround Remains a Long Haul
Q2 shows financial discipline and early commercial traction, but management keeps the bar low for 2026.
XRAY · Earnings Call · 2026-08-06
A Quarter of Financial Discipline and Timely Refunds
Dentsply Sirona's second-quarter 2026 results were a study in disciplined financial management under pressure. Revenue fell 4.1% as reported to $898 million, and adjusted EPS was flat at $0.52 — but the quarter was saved by a tariff refund that boosted EPS by $0.17. Management used part of that windfall to repurchase 1.3 million shares at an average price below $10, the first buyback since Q3 2024, and CFO John Fortson stressed working capital improvements and debt reduction as priorities. “Adjusted EBITDA margins were approximately flat year over year with the benefit from $44 million in tariff refunds offset by a decline in gross profit driven by lower volumes, sales mix, incremental tariff impacts.” — John C. Fortson, Executive Vice President and Chief Financial Officer · 2026-08-06 The company's leverage position remains a concern: effective net cash was -$1.8 billion, a 52% year-over-year improvement, but still a large net debt position that management is prioritizing with debt reduction.Recommercializing the Platform
The growth action plan is now six months old, and management points to early traction: expanded distributor relationships (Atlanta Dental, Nashville Dental, Medline Sinclair in Canada), certification of all US implant reps, and clinical education events. Yet the tone remains cautious. CEO Daniel Scavilla noted that some of the new dealers are already growing double digits: “What I have seen in particular without calling out names are 2 of the new dealers that have grown double digits so far.” — Daniel T. Scavilla, President and Chief Executive Officer · 2026-08-06 But the US remains the crux, and the company is still working through EMEA distributor destocking, where inventory levels have dropped from 12 weeks to 8 weeks at some private-equity-owned dealers. The CFO's emphasis on working capital links directly to the education program investments being made in sales force and clinical training, with the benefits expected to show up more in the fourth quarter.The Road Ahead: Still a Turnaround
The guidance for 2026 remains unchanged at $3.5–3.6 billion in net sales and $1.40–1.50 adjusted EPS, excluding tariffs. John Fortson and Dane Scavilla both acknowledge that Q3 will be below Q2 on the bottom line, with the payoff arriving in Q4. Scavilla sees the US exiting the year with a positive growth rate: “When you hear the reports out from competitors about the market stabilization, I agree with them. ... I think we would have negative Q1, negative Q2, I am thinking somewhat more favorable, not positive, but little more favorable or less loss. In Q3. And I am looking in The US to exit the year with a plus sign.” — Daniel T. Scavilla, President and Chief Executive Officer · 2026-08-06 This is consistent with the prior quarter's message that the plan is a two-year effort—not a quick fix. As Scavilla said back in May: “When we first rolled out the return to growth plan, we called it a 24-month plan, recognizing that you cannot move fast enough, but at the same time, cannot change this in the speed that all of us would wish.” — Daniel T. Scavilla, Chief Executive Officer · 2026-05-05 The shift to a drop-ship model with dealers, highlighted in the prior call, is also slowly unwinding: “But what we're doing is rather than selling into dealer inventory like we've done in the past, we're going into a drop-ship model.” — Daniel Scavilla, President and Chief Executive Officer · 2026-02-27 The market seems to be pricing in the long lead time; the stock is down 84% from its 2021 peak and remains in a prolonged drawdown. Management's own tone underscores the patience required.We are making progress, but this is still a turnaround.